BPC-157 vs TB-500: What the Research Literature Says

These two compounds get mentioned in the same breath constantly, usually as if they were interchangeable or as if one were simply a stronger version of the other. Structurally they have nothing in common, and the published literature studies them through different mechanisms. Here's what actually separates them, and what that means when you're evaluating a supplier's Certificate of Analysis for either one.

At a glance

BPC-157: a defined sequence

BPC-157 is a synthetic peptide of fifteen amino acids. Its sequence corresponds to a portion of a larger protein identified in gastric juice, which is where the "Body Protection Compound" name originates. Unlike many research peptides, it isn't a fragment of a hormone or a receptor-targeted analogue — it's a stable sequence that has been studied largely for its effects on tissue in animal models.

The preclinical literature is reasonably substantial and comes disproportionately from a small number of research groups. Published work has examined it in rodent models of tendon and ligament injury and in gastrointestinal models — for example, Chang and colleagues reported effects on tendon fibroblast behaviour in cell and animal work. Mechanistically, the studies that have looked at pathways point toward angiogenesis and growth-factor signalling.

Two things are worth being clear-eyed about. First, the overwhelming majority of this work is in rodents, and rodent tissue-repair results have a long history of not translating cleanly to humans. Second, human clinical data is very limited. Anyone presenting BPC-157 as an established human therapeutic is going well beyond what the literature supports.

TB-500: a naming problem before a science problem

Thymosin β4 is a naturally occurring 43-amino-acid protein present in most cell types, and one of its best-characterised roles is binding actin — the protein that forms much of a cell's structural scaffolding. By sequestering actin monomers, it influences how cells reorganise their internal structure, which is closely tied to cell migration. That migration behaviour is why it appears in wound-healing and tissue-repair literature, including work by Bock-Marquette and colleagues on ligament and cardiac tissue models.

"TB-500" is where it gets murky. The label is commonly used for a synthetic peptide corresponding to the active actin-binding region rather than the full protein — but it is not applied consistently across the industry. Some material sold under that name is the short fragment; some is full-length Thymosin β4; occasionally the two get conflated in the same product listing.

This matters more than it sounds. If two suppliers sell "TB-500" and one is shipping a seven-residue fragment while the other ships a 43-residue protein, those are different molecules with different molecular weights — and any experiment comparing results across them isn't comparing like with like.

Handling and storage: effectively identical

For all their differences on paper, these two behave similarly in the lab. Both arrive lyophilized in sealed vials and are stable in that state when kept cold, sealed and out of the light. Both are reconstituted with bacteriostatic water, and both have a substantially shorter usable window once in solution — refrigerated, and handled to avoid repeated freeze-thaw cycles.

If you're setting up handling procedures for either, our guides on storage and reconstitution and what bacteriostatic water is cover the practical side, and what lyophilized means explains why they ship as powder in the first place.

Evaluating either one from a supplier

The questions worth asking are the same for both, and they're not really about the compound:

• Is the COA batch-specific? A certificate should carry a batch or lot number matching the code printed on your vial. A generic PDF reused across every order tells you nothing about what you received. Our guide on batch codes and traceability covers how this should work.
• Does it include mass spectrometry, not just HPLC? HPLC tells you how pure the sample is. Mass spec tells you what it is. For TB-500 in particular, skipping the second question is a real gap. See how to read a peptide COA.
• Is net peptide content reported? Purity and net peptide content are different figures, and the difference is often meaningful. Our guide on what ≥99% actually means unpacks this.
• Is the testing third-party? In-house numbers with no independent lab behind them are a claim, not evidence. How to verify a peptide supplier is the fuller checklist.

So which is "better"?

It isn't a meaningful question as usually asked. They're structurally unrelated compounds studied through different mechanisms in different model systems — the comparison is closer to "which reagent is better" than "which is the stronger version." What a researcher actually chooses depends on the model system and the pathway under investigation, and that's a decision for the study design, not for a supplier's website.

What we can be useful about is the supply side: whether the material in the vial is what the label says, whether the batch is traceable, and whether an independent lab confirmed it. That's the part a supplier is accountable for.